Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.15B -14.7% |
| Revenue (ttm) | 890.79M +33.5% |
| Net Income | 33.50M +183.8% |
| EPS | 0.10 +174.8% |
| Shares Out | 339.78M |
| PE Ratio | 94.43 |
| Forward PE | 501.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 413,435 |
| Open | 9.26 |
| Previous Close | 9.54 |
| Day's Range | 9.11 - 9.30 |
| 52-Week Range | 6.28 - 13.11 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 20.49 (+123.93%) |
| Earnings Date | Oct 22, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $20.49, which is an increase of 123.93% from the latest price.
News
Telix Pharmaceuticals falls -9.9%
Telix Pharmaceuticals (TLX) is down -9.9%, or -$1.10 to $10.06.
Telix Shares Sink Nearly 10% as Investors Shrug Off 19% Revenue Growth and Pixclara Launch in Third Quarter
Telix Pharmaceuticals shares fell sharply after third-quarter revenue growth showed no acceleration, despite strong demand for imaging products and progress in its cancer pipeline.
Telix Pharmaceuticals falls -10.1%
Telix Pharmaceuticals (TLX) is down -10.1%, or -$1.13 to $10.03.
Telix Pharmaceuticals (TLX) Reports Q3 Revenue Growth, Reaffirms FY 2026 Guidance
Telix Pharmaceuticals (TLX) Reports Q3 Revenue Growth, Reaffirms FY 2026 Guidance
Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a financial update reflecting a 19% increase in group revenue and key operational highlights for the third quarter en...
Telix Pharmaceuticals Shares Slide 6.6% as Radiopharmaceutical Stock Extends Volatile 2026 Run on the ASX
Telix Pharmaceuticals shares fell 6.6% to A$14.72, extending a volatile period as investors weigh strong revenue growth against rising costs, valuation concerns and regulatory risks.
Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30...
Telix Pharmaceuticals Confirms FY26 Revenue Target Above $1 Billion, Ticker TLX
Telix Pharmaceuticals Confirms FY26 Revenue Target Above $1 Billion, Ticker TLX
Telix Pharmaceuticals reports Q2 group revenue $245M vs. $206M last year
Christian Behrenbruch, Managing Director and Group CEO, stated, “Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in...
Telix Pharmaceuticals reaffirms FY26 revenue and other income view $1B
Telix reaffirmed that FY26 revenue and other income is expected to be in excess of $1B, with revenue tracking in line with upper end of FY26 guidance of $950M-$970M plus…
Telix Reports Third Quarter 2026 Financial Performance
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational pe...
Telix Pharmaceuticals Earnings release: Q3 2026
Telix Pharmaceuticals released its Q3 2026 earnings on October 20, 2026, summarizing the period's financial results.
Telix, Ekalia enter pact to advance U.S. production of astatine-211
Telix Pharmaceuticals (TLX) and Ekalia, a joint venture between Ion Beam Applications and Framatome, announced a collaboration to advance scalable United States production of astatine-211, an alpha-em...
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint vent...
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary role...
Profound Medical enters co-education agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate uro...
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides...
First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug
(RTTNews) - Telix Pharmaceuticals Limited (TLX) announced that the first U.S. patient has been dosed with Pixclara (floretyrosine F 18 or 18F-FET), marking the commercial launch of the company's FDA-a...
Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients
Telix Pharmaceuticals (TLX) announced that the first patients in the U.S. have been dosed with Pixclara – floretyrosine F 18 or 18F-FET -, its FDA-approved, amino acid positron emission tomography,…
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U....
Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology
(RTTNews) - Ion Beam Applications S.A. (IBAB.BR), a medical technology company, on Thursday announced a new agreement with ARTMS Inc., a subsidiary of Telix Pharmaceuticals Inc. (TLX) to distribute it...
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is que...
Telix Pharmaceuticals Limited Research and Development Day Transcript
Telix Pharmaceuticals Limited Research and Development Day Transcript